TheraNest vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management and therapy notes software for mental health practitioners, acquired by Therapy Brands. Serves solo practices, group practices, and agencies.
About
TheraNest is a cloud-based practice management and clinical documentation platform for mental health practitioners, including therapists, social workers, counselors, and psychologists. Originally founded as an independent company, TheraNest was acquired by Therapy Brands, a technology roll-up focused on behavioral health software, which also owns Therapy Brands, ICANotes, and other mental health practice management systems. TheraNest serves a broad range of practice types from solo practitioners to large group practices and nonprofit agencies.\n\nThe platform provides scheduling, billing, telehealth, clinical notes, treatment planning, and client portal functionality in a unified interface. TheraNest is particularly recognized for its affordability and straightforward pricing model, which has made it a popular choice for practices with tight administrative budgets and those serving Medicaid populations. The product supports both individual and group therapy documentation workflows, including co-signature and supervision features relevant to practices employing pre-licensed associates.\n\nAs part of the Therapy Brands portfolio, TheraNest benefits from shared infrastructure investment and cross-selling opportunities, while maintaining its standalone brand and product identity. The mental health EHR market is competitive, with SimplePractice, TherapyNotes, and Jane App also vying for the small-to-mid-size practice segment. TheraNest's acquisition has allowed it to invest in product development while leveraging Therapy Brands' broader customer relationships and compliance infrastructure.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.